secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-07-07T23:59:59+00:00
Accession:  0001213900-23-055559
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma shareholders approve reverse stock split authority up to 1-for-15
--------------------------------------------------------------------------------

- Special meeting held July 7, 2023; quorum of 19,044,974 shares (57.57% voting power) present.
- Proposal approved with 18,631,480 votes for, 413,494 against, 0 abstentions.
- Board authorized to effect one or more reverse splits up to 1-for-15 at any time before July 7, 2024.
- Company intends to implement a reverse split in the near future; will file a subsequent 8-K.
- No further details on split ratio or timing provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023055559/0001213900-23-055559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023055559/ea181507-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-055559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer